Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Neoadjuvant nivolumab
DRUG
2 trials
Sponsors
Universitätsklinikum Hamburg-Eppendorf
, The Netherlands Cancer Institute
Conditions
Head and Neck Cancer
Renal Cell Carcinoma
Phase 2
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
Active, not recruiting
NCT05148546
The Netherlands Cancer Institute
Renal Cell Carcinoma
Start: 2022-04-28
End: 2029-04-30
Target: 69
Updated: 2025-09-30
Phase 3
Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy
NCT03700905
Universitätsklinikum Hamburg-Eppendorf
Head and Neck Cancer
Start: 2018-08-21
End: 2024-05-31
Target: 276
Updated: 2023-05-23
Related Papers
Phase III Study of Nivolumab Alone or Combined with Ipilimumab as Immunotherapy Versus Standard of Care in Resectable Head and Neck Squamous Cell Carcinoma
Future Oncology
2020-09-09
31 citations
Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.
Journal of Clinical Oncology
2019-05-20
2 citations